C4 Therapeutics, INC 8-K filings

NASDAQ

8 May 2024

CCCC

8-K: C4 Therapeutics Reports Q1 2024 Financial Results and Business Highlights, Secures $8 Million Milestone Payment

C4 Therapeutics announced its first quarter 2024 financial results, highlighted by an $8 million milestone payment from Biogen and a new research collaboration with Merck KGaA.

NASDAQ

8 Mar 2024

CCCC

C4 Therapeutics, INC

8-K: C4 Therapeutics Reprices Underwater Stock Options to Retain Key Talent

C4 Therapeutics has repriced stock options for employees, including some executives, to better align incentives and retain talent.

NASDAQ

4 Mar 2024

CCCC

C4 Therapeutics, INC

8-K: C4 Therapeutics Inks $740 Million Collaboration Deal with Merck KGaA for Targeted Protein Degraders

C4 Therapeutics has entered into a research collaboration and license agreement with Merck KGaA, potentially worth up to $740 million, to develop two targeted protein degraders for cancer treatment.

NASDAQ

22 Feb 2024

CCCC

C4 Therapeutics, INC

8-K: C4 Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

C4 Therapeutics announced its full year 2023 financial results, highlighted by progress in clinical trials for CFT7455 and CFT1946, new collaborations, and a strengthened cash position.

NASDAQ

11 Jan 2024

CCCC

C4 Therapeutics, INC

8-K: C4 Therapeutics Announces Pipeline Progress and Extended Cash Runway into 2027

C4 Therapeutics provides an update on its clinical programs, including positive data from its CFT7455 trial, and announces a restructuring that extends its cash runway into 2027.